A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple Sclerosis

Clinical trial NCT03737851 · COMPLETED

Trial details

NCT number: NCT03737851
Sponsor: AbbVie
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Multiple Sclerosis (MS)

Start date: 2018-12-11
Primary completion: 2021-08-09
Enrollment: 208

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.